Titomirov: Informax Seeks to Grow Business Through Collaborations | GenomeWeb

NEW YORK, Feb 6 – Informax's business strategy entails looking beyond off-the-shelf sales of its software toward developing hands-on collaborations, such as the partnership the company forged with Axcell Biosciences, Informax CEO Alex Titomirov said Tuesday.

“We’d like to have collaborations and technologies that map [bioinformatics] onto development,” Titomirov told GenomeWeb following a media seminar in New York.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.